Literature DB >> 30485204

Intravenous infusion of mesenchymal stem cells for protection against brainstem infarction in a persistent basilar artery occlusion model in the adult rat.

Ai Namioka1, Takahiro Namioka1, Masanori Sasaki1,2, Yuko Kataoka-Sasaki1, Shinichi Oka1, Masahito Nakazaki1, Rie Onodera1, Junpei Suzuki1, Yuichi Sasaki1, Hiroshi Nagahama1, Jeffery D Kocsis3,2, Osamu Honmou1,2.   

Abstract

OBJECTIVE: Morbidity and mortality in patients with posterior circulation stroke remains an issue despite advances in acute stroke therapies. The intravenous infusion of mesenchymal stem cells (MSCs) elicits therapeutic efficacy in experimental supratentorial stroke models. However, since there are few reliable animal models of ischemia in the posterior circulation, the therapeutic approach with intravenous MSC infusion has not been tested. The objective of this study was to test the hypothesis that intravenously infused MSCs provide functional recovery in a newly developed model of brainstem infarction in rats.
METHODS: Basilar artery (BA) occlusion (BAO) was established in rats by selectively ligating 4 points of the proximal BA with 10-0 nylon monofilament suture. The intravenous infusion of MSCs was performed 1 day after BAO induction. MRI and histological examinations were performed to assess ischemic lesion volume, while multiple behavioral tests were performed to evaluate functional recovery.
RESULTS: The MSC-treated group exhibited a greater reduction in ischemic lesion volume, while behavioral testing indicated that the MSC-infused group had greater improvement than the vehicle group 28 days after the MSC infusion. Accumulated infused MSCs were observed in the ischemic brainstem lesion.
CONCLUSIONS: Infused MSCs may provide neuroprotection to facilitate functional outcomes and reduce ischemic lesion volume as evaluated in a newly developed rat model of persistent BAO.

Entities:  

Keywords:  ACB = anterior cerebellar branch; AICA = anterior inferior cerebellar artery; BA = basilar artery; BAO = basilar artery occlusion; FITC = fluorescein isothiocyanate; MCAO = middle cerebral artery occlusion; MSC = mesenchymal stem cell; mNSS = modified neurological severity score; mesenchymal stem cell; stroke; transplantation; vascular disorders

Year:  2018        PMID: 30485204     DOI: 10.3171/2018.4.JNS173121

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  4 in total

1.  Safety and Efficacy of Intraventricular Delivery of Bone Marrow-Derived Mesenchymal Stem Cells in Hemorrhagic Stroke Model.

Authors:  Peng Huang; William D Freeman; Brandy H Edenfield; Thomas G Brott; James F Meschia; Abba C Zubair
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

Review 2.  Mesenchymal Stem Cells for Neurological Disorders.

Authors:  Anna Andrzejewska; Sylwia Dabrowska; Barbara Lukomska; Miroslaw Janowski
Journal:  Adv Sci (Weinh)       Date:  2021-02-24       Impact factor: 16.806

3.  Intravenous Infusion of Autoserum-Expanded Autologous Mesenchymal Stem Cells in Patients With Chronic Brain Injury: Protocol for a Phase 2 Trial.

Authors:  Shinichi Oka; Tomohiro Yamaki; Masanori Sasaki; Ryo Ukai; Mitsuhiro Takemura; Takahiro Yokoyama; Yuko Kataoka-Sasaki; Rie Onodera; Yoichi M Ito; Shigeki Kobayashi; Jeffery D Kocsis; Yasuo Iwadate; Osamu Honmou
Journal:  JMIR Res Protoc       Date:  2022-07-06

4.  Intravenous infusion of bone marrow-derived mesenchymal stem cells improves tissue perfusion in a rat hindlimb ischemia model.

Authors:  Shusaku Maeda; Takuji Kawamura; Masanori Sasaki; Kazuo Shimamura; Takashi Shibuya; Akima Harada; Osamu Honmou; Yoshiki Sawa; Shigeru Miyagawa
Journal:  Sci Rep       Date:  2022-10-10       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.